OREANDA-NEWS. JSC „Grindeks” today announces that starting from January 12, 2016 in accordance with the decision of the Supervisory Council of JSC „Grindeks” Janis Romanovskis who is also the Chief Finance and Administrative Officer of JSC „Grindeks” has been elected as the Member of the Board of JSC „Grindeks”.

Janis Romanovskis had also previously worked at „Grindeks” as the Chairman of the Board and Chief Finance and Administrative Officer. During his career Romanovskis has been the Chairman of the Board of pharmaceutical companies „Recipe plus” and „Sentor Farm aptiekas”, as well as the Finance Director of the IT company „Komerccentrs DATI Grupa” and the Head of the Financial Management Unit of JSC „Dati”.   

Born in 1960, Janis Romanovskis graduated from Riga Secondary School No. 1, Faculty of Economics of University of Latvia and Riga International School of Economics and Business Administration.

Janis Romanovskis does not own shares of JSC „Grindeks”.

The Chairman of the Board of JSC „Grindeks” Juris Bundulis and Member of the Board, Commercial Director Ibraim Muhtsi will continue their work at the Board of JSC „Grindeks”. 

“Grindeks” is an international, vertically integrated pharmaceutical company. Main fields of action are research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients. The Group of “Grindeks” consists of five subsidiary companies in Latvia, Estonia, Russia and Slovakia as well as representative offices in 13 countries.

“Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of generics included therein. Currently “Grindeks” produces 25 active pharmaceutical ingredients.

Products of the company are exported to 60 countries and its export comprises 94% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, the Netherlands, Germany, Canada, the U.S., France, Ireland and Japan.

To increase production capacity and develop infrastructure, since 2002 the company has accomplished many significant investment projects, investing more than 70 million euros over the years.